Role of Receptor Profiling for Personalized Therapy in a Patient with a Growth Hormone-Secreting Macroadenoma Resistant to First-Generation Somatostatin Analogues

Alexandraki, Krystallenia Ι.; Papadimitriou, Eirini; Mavroeidi, Vasiliki; Kyriakopoulos, Georgios; Xydakis, Antonios M.; Papaioannou, Theodore G.; Kolomodi, Denise; Kaltsas, Gregory; Grossman, Ashley

doi:10.3390/jpm9040048

Cited by 5 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…biomarker) of a tumour, and then targeting the treatment to the identified biomarkers for individualized treatment regimens. 99,100 This has already been seen in somatotroph PTs, where the different immunohistochemical profiles may assist with the identification of subgroups of patients that may benefit from similar treatments . 100 In addition, it could identify genetic alterations that may have an impact on the outcome of different therapies by targeting specific molecular pathways.…”

Section: Discussionmentioning

confidence: 91%

“…99,100 This has already been seen in somatotroph PTs, where the different immunohistochemical profiles may assist with the identification of subgroups of patients that may benefit from similar treatments . 100 In addition, it could identify genetic alterations that may have an impact on the outcome of different therapies by targeting specific molecular pathways. An important step in this direction was introduced with the new classification of PTs that included transcription factors.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Prognostic Biomarkers in Pituitary Tumours: A Systematic Review

Papadimitriou,

Chatzellis,

Dimitriadi

et al. 2023

touchREVIEWS in Endocrinology

Self Cite

View full text Add to dashboard Cite

Pituitary tumours (PTs) are the second most common intracranial tumour. Although the majority show benign behaviour, they may exert aggressive behaviour and can be resistant to treatment. The aim of this review is to report the recently identified biomarkers that might have possible prognostic value. Studies evaluating potentially prognostic biomarkers or a therapeutic target in invasive/recurrent PTs compared with either non-invasive or non-recurrent PTs or normal pituitaries are included in this review. In the 28 included studies, more than 911 PTs were evaluated. A systematic search identified the expression of a number of biomarkers that may be positively correlated with disease recurrence or invasion in PT, grouped according to role: (1) insensitivity to anti-growth signals: minichromosome maintenance protein 7; (2) evasion of the immune system: cyclooxygenase 2, arginase 1, programmed cell death protein 1 (PD-1)/ programmed death ligand 2, cluster of differentiation (CD) 80/CD86; (3) sustained angiogenesis: endothelial cell-specific molecule, fibroblast growth factor receptor, matrix metalloproteinase 9, pituitary tumour transforming gene; (4) self-sufficiency in growth signals: epidermal growth factor receptor; and (5) tissue invasion: matrix metalloproteinase 9, fascin protein. Biomarkers with a negative correlation with disease recurrence or invasion include: (1) insensitivity to anti-growth signals: transforming growth factor β1, Smad proteins; (2) sustained angiogenesis: tissue inhibitor of metalloproteinase 1; (3) tissue invasion: Wnt inhibitory factor 1; and (4) miscellaneous: co-expression of glial fibrillary acidic protein and cytokeratin, and oestrogen receptors α36 and α66. PD-1/ programmed cell death ligand 1 showed no clear association with invasion or recurrence, while cyclin A, cytotoxic T lymphocyte-associated protein 4, S100 protein, ephrin receptor, galectin-3, neural cell adhesion molecule, protein tyrosine phosphatase 4A3 and steroidogenic factor 1 had no association with invasion or recurrence of PT. With the aim to develop a more personalized approach to the treatment of PT, and because of the limited number of molecular targets currently studied in the context of recurrent PT and invasion, a better understanding of the most relevant of these biomarkers by well-designed interventional studies will lead to a better understanding of the molecular profile of PT. This should also meet the increased need of treatable molecular targets.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 91%

Prognostic Biomarkers in Pituitary Tumours: A Systematic Review

Papadimitriou,

Chatzellis,

Dimitriadi

et al. 2023

touchREVIEWS in Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Receptor profiling and possibly the molecular characterization of pituitary tumors may guide an individualized therapeutic plan [16].…”

Section: Discussionmentioning

confidence: 99%

Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course

et al. 2021

View full text Add to dashboard Cite

Somatostatin analogues are considered to be the first line of treatment in acromegaly. Somatostatin analogues of the first generation mainly target the somatostatin receptor (SSTR) subtype 2 and have been proven efficient in the majority of patients with acromegaly. Pasireotide was the first somatostatin analogue also substantially targeting the SSTR subtype 5. An efficient drug for Cushing’s disease tailored to suboptimal-responding patients with acromegaly then became available. We immunohistochemically investigated SSTR subtypes expression in pituitary adenomas from operated acromegaly patients with clinical relapse and a complicated clinical course. Patients received pasireotide in the course of their disease. The predictive value of SSTR subtypes immunhistochemical analysis for the therapeutic response is discussed.

show abstract